<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE- moexipril hydrochloride and hydrochlorothiazide tablet, film coated </strong><br>Glenmark Generics Inc., USA<br></p></div>
<h1><span class="Bold">Moexipril Hydrochloride and Hydrochlorothiazide Tablets<br>7.5 mg/12.5 mg, 15 mg/12.5 mg and 15 mg/25 mg</span></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3a77a7aa-0908-4a15-b697-00565feeec83"></a><a name="section-1"></a><p></p>
<p class="First"><span class="Bold">Rx Only</span></p>
<div class="Warning">
<a name="i4i_table_ID_s34066-1"></a><a name="section-1.1"></a><p></p>
<h2>WARNING: FETAL TOXICITY </h2>
<dl>
<dt>•</dt>
<dd><span class="Bold">When pregnancy is detected, discontinue moexipril hydrochloride and hydrochlorothiazideas soon as possible. </span></dd>
<dt>•</dt>
<dd><span class="Bold">Drugs that act directly on the renin-angiotensin system can cause injury and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> to the developing fetus. See <a href="#i4i_section_id_440e1731-3c7e-4a2a-9fbb-a39526afc69a">WARNINGS: Fetal Toxicity</a></span></dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_s34089-3"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION </h1>
<p class="First">Moexipril hydrochloride and hydrochlorothiazide tablets are a combination of an angiotensin-converting enzyme (ACE) inhibitor, moexipril hydrochloride, and a diuretic, hydrochlorothiazide USP. Moexipril hydrochloride is a fine white to off-white powder. It is soluble (about 10% weight-to-volume) in distilled water at room temperature. It has the empirical formula C<span class="Sub">27</span>H<span class="Sub">34</span>N<span class="Sub">2</span>O<span class="Sub">7</span>•HCl and a molecular weight of 535.04. It is chemically described as [3S-[2[R*(R*)],3R*]]-2-[2-[[1-(Ethoxycarbonyl)-3-phenyl-propyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquino-linecarboxylic acid, monohydrochloride. Moexipril hydrochloride is a non-sulfhydryl containing precursor of the active ACE inhibitor moexiprilat and its structural formula is: </p>
<div class="Figure">
<a name="id609"></a><img alt="Structural formula of Moexipril Hydrochloride" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e71002c8-3463-4950-b984-c4eee356a5f2&amp;name=30b478aa-eb7f-4a97-9cd0-edfc0f368e7a-01.jpg">
</div>
<p>Hydrochlorothiazide USP is a white, or practically white, crystalline powder. It is slightly soluble in water, freely soluble in sodium hydroxide solution, in n-butylamine and in dimethylformamide. Hydrochlorothiazide USP has the empirical formula C<span class="Sub">7</span>H<span class="Sub">8</span>ClN<span class="Sub">3</span>O<span class="Sub">4</span>S<span class="Sub">2</span> and a molecular weight of 297.75. It is chemically described as 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-,1,1-dioxide. Hydrochlorothiazide USP is a thiazide diuretic and its structural formula is:</p>
<div class="Figure">
<a name="id617"></a><img alt="Structural formula of Hydrochlorothiazide" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e71002c8-3463-4950-b984-c4eee356a5f2&amp;name=30b478aa-eb7f-4a97-9cd0-edfc0f368e7a-02.jpg">
</div>
<p>Moexipril hydrochloride and hydrochlorothiazide tablets are available for oral administration in three tablet strengths. The inactive ingredients in all strengths are crospovidone, lactose monohydrate, magnesium oxide, magnesium stearate and povidone. The film-coating in all strengths contains hydroxypropyl cellulose, hypromellose, polyethylene glycol 6000, magnesium stearate and titanium dioxide. In addition, the film coating for moexipril hydrochloride and hydrochlorothiazide tablets 7.5 mg/12.5 mg and moexipril hydrochloride and hydrochlorothiazide tablets 15 mg/25 mg contains ferric oxide yellow. </p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_s34090-1"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY </h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_c5e6bd8c-ac58-4b95-b60f-d125e13ed677"></a><a name="section-3.1"></a><p></p>
<h2>Mechanism of Action </h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9d29b1fe-bfc1-4a47-aa4f-ed834ed31419"></a><a name="section-3.1.1"></a><p></p>
<h3>Moexipril Hydrochloride</h3>
<p class="First">Moexipril hydrochloride is a prodrug for moexiprilat, which inhibits ACE in humans and animals. The mechanism through which moexiprilat lowers blood pressure is believed to be primarily inhibition of ACE activity. ACE is a peptidyl dipeptidase that catalyzes the conversion of the inactive decapeptide angiotensin I to the vasoconstrictor substance angiotensin II. Angiotensin II is a potent peripheral vasoconstrictor that also stimulates aldosterone secretion by the adrenal cortex and provides negative feedback on renin secretion. ACE is identical to kininase II, an enzyme that degrades bradykinin, an endothelium-dependent vasodilator. Moexiprilat is about 1000 times as potent as moexipril in inhibiting ACE and kininase II. Inhibition of ACE results in decreased angiotensin II formation, leading to decreased <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">vasoconstriction</span>, increased plasma renin activity, and decreased aldosterone secretion. The latter results in <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> and natriuresis and a small increase in serum potassium concentration (mean increases of about 0.25 mEq/L were seen when moexipril was used alone).</p>
<p>Whether increased levels of bradykinin, a potent vasodepressor peptide, play a role in the therapeutic effects of moexipril remains to be elucidated. Although the principal mechanism of moexipril in blood pressure reduction is believed to be through the renin-angiotensin-aldosterone system, ACE inhibitors have some effect on blood pressure even in apparent low-renin <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. As is the case with other ACE inhibitors, however, the antihypertensive effect of moexipril is smaller in black patients, a predominantly low-renin population, than in non-black hypertensive patients. Although moexipril monotherapy is less effective in blacks than in nonblacks, the efficacy of combination therapy appears to be independent of race. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_23e4cdf4-33b4-403b-973f-1b98324c44d4"></a><a name="section-3.1.2"></a><p></p>
<h3>Hydrochlorothiazide</h3>
<p class="First">Hydrochlorothiazide is a thiazide diuretic and antihypertensive. Thiazides affect the distal renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts. Indirectly, the diuretic action of hydrochlorothiazide, reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium. The renin-aldosterone link is mediated by angiotensin, so coadministration of an ACE inhibitor tends to reverse the potassium loss associated with these diuretics. The mechanism of the antihypertensive effect of thiazides is unknown.</p>
</div>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_36ab09a6-1a11-4c45-8ae1-b3cd98b461d0"></a><a name="section-3.2"></a><p></p>
<h2>Pharmacokinetics </h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_af036d5e-2b73-4d08-9eeb-ef4d2bb15484"></a><a name="section-3.2.1"></a><p></p>
<h3>Moexipril-Hydrochlorothiazide</h3>
<p class="First">Following oral administration of moexipril hydrochloride and hydrochlorothiazide, the moexipril peak plasma concentration was reached within 0.8 hour and the peak plasma concentration of moexiprilat occurred 1.6 hours after administration. After reaching the peak plasma level (C<span class="Sub">max</span>), moexiprilat plasma concentrations decreased biphasically. After administration of moexipril hydrochloride and hydrochlorothiazide, renal excretion of unchanged hydrochlorothiazide is about 60% in 24 hours. The pharmacokinetics of moexipril and hydrochlorothiazide after administration of moexipril hydrochloride and hydrochlorothiazide are not different, respectively, from the pharmacokinetics of moexipril and hydrochlorothiazide from immediate-release monotherapy formulations.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e585d9ba-7f22-4cb7-adfe-aa9dd4271f33"></a><a name="section-3.2.2"></a><p></p>
<h3>Moexipril Hydrochloride</h3>
<p class="First">Moexipril’s antihypertensive activity is almost entirely due to its deesterified metabolite, moexiprilat. Bioavailability of oral moexipril is about 13% compared to intravenous (I.V.) moexipril (both measuring the metabolite moexiprilat), and is markedly affected by food, which reduces C<span class="Sub">max</span> and AUC (see Absorption). Moexipril should therefore be taken in a fasting state. The time of peak plasma concentration (T<span class="Sub">max</span>) of moexiprilat is about 1 ½ hours and elimination half-life (t<span class="Sub">1/2</span>) is estimated at 2 to 9 hours in various studies, the variability reflecting a complex elimination pattern that is not simply exponential. Like all ACE inhibitors, moexiprilat has a prolonged terminal elimination phase, presumably reflecting slow release of drug bound to the ACE. Accumulation of moexiprilat with repeated dosing is minimal, about 30%, compatible with a functional elimination t<span class="Sub">1/2</span> of about 12 hours. Over the dose range of 7.5 to 30 mg, pharmacokinetics are approximately dose proportional.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1842a0f4-e2e2-4acb-9cb6-944fc50fb8c8"></a><a name="section-3.2.2.1"></a><p></p>
<h4>Absorption: </h4>
<p class="First">Moexipril is incompletely absorbed, with bioavailability as moexiprilat of about 13%. Bioavailability varies with formulation and food intake which reduces C<span class="Sub">max</span> and AUC of moexiprilat by about 70% and 40% respectively after the ingestion of a low-fat breakfast or by 80% and 50% respectively after the ingestion of a high-fat breakfast.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0d38c86c-a96a-457e-a7b0-2d696687067a"></a><a name="section-3.2.2.2"></a><p></p>
<h4>Distribution: </h4>
<p class="First">The clearance (CL) for moexipril is 441 mL/min and for moexiprilat 232 mL/min with a t<span class="Sub">1/2</span> of 1.3 and 9.8 hours, respectively. Moexiprilat is about 50% protein bound. The volume of distribution of moexiprilat is about 2.8 L/kg.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8d60bb63-3098-47c2-812a-60016a9dad8b"></a><a name="section-3.2.2.3"></a><p></p>
<h4>Metabolism and Excretion: </h4>
<p class="First">Moexipril is relatively rapidly converted to its active metabolite moexiprilat, but persists longer than some other ACE inhibitor prodrugs, such that its t <span class="Sub">½</span> is over one hour and it has a significant AUC. Both moexipril and moexiprilat are converted to diketopiperazine derivatives and unidentified metabolites. After I.V. administration of moexipril, about 40% of the dose appears in urine as moexiprilat, about 26% as moexipril, with small amounts of the metabolites; about 20% of the I.V. dose appears in feces, principally as moexiprilat. After oral administration, only about 7% of the dose appears in urine as moexiprilat, about 1% as moexipril, with about 5% as other metabolites. Fifty-two percent of the dose is recovered in feces as moexiprilat and 1% as moexipril. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2f2a480b-e67f-4fa0-8f27-203d6ee80a4f"></a><a name="section-3.2.2.4"></a><p></p>
<h4>Special Populations:</h4>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b55ffd4b-4c11-4dcc-8a51-76db80c4db89"></a><a name="section-3.2.2.4.1"></a><p></p>
<h5>Decreased Renal Function: </h5>
<p class="First">The effective elimination t<span class="Sub">½</span> and AUC of both moexipril and moexiprilat are increased with decreasing renal function. There is insufficient information available to characterize this relationship fully, but at creatinine clearances in the range of 10 to 40 mL/min, the t<span class="Sub">½</span> of moexiprilat is increased by a factor of 3 to 4.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_95e5348f-ea9d-4b3f-8c19-81b667155a59"></a><a name="section-3.2.2.4.2"></a><p></p>
<h5>Decreased Hepatic Function: </h5>
<p class="First">In patients with mild to moderate cirrhosis given single 15 mg doses of moexipril, the C<span class="Sub">max</span> of moexipril was increased by about 50% and the AUC increased by about 120%, while the C<span class="Sub">max</span> for moexiprilat was decreased by about 50% and the AUC increased by almost 300%.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_dd1a306c-5ca5-4c6d-b8c7-507e57d75075"></a><a name="section-3.2.2.4.3"></a><p></p>
<h5>Elderly Patients: </h5>
<p class="First">In elderly male subjects (65 to 80 years old) with clinically normal renal and hepatic function, the AUC and C<span class="Sub">max</span> of moexiprilat are about 30% greater than in younger subjects (19 to 42 years old).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_257fe780-37e5-47c4-895a-e42a760bf947"></a><a name="section-3.2.2.4.4"></a><p></p>
<h5><span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">Pharmacokinetic Interactions</span> With Other Drugs:  </h5>
<p class="First">No clinically important <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interactions</span> occurred when moexipril was administered concomitantly with hydrochlorothiazide, digoxin, or cimetidine. </p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_428d745c-6304-4cce-88ce-4a5a05cdaaa0"></a><a name="section-3.2.3"></a><p></p>
<h3>Hydrochlorothiazide</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d032b7af-5d22-4652-b306-fa01839ab42b"></a><a name="section-3.2.3.1"></a><p></p>
<h4>Absorption:</h4>
<p class="First">After oral administration, 60 to 80% of a single-dose of hydrochlorothiazide is absorbed. The reported studies of food effects on hydrochlorothiazide absorption have been inconclusive. The absorption of hydrochlorothiazide is reported to be reduced by 50% in patients with <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>. Hydrochlorothiazide exhibits dose proportionality over the dose range of 12.5 to 75 mg.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9c920139-9979-43cf-af60-d548a08037ad"></a><a name="section-3.2.3.2"></a><p></p>
<h4>Distribution:</h4>
<p class="First">The apparent volume of distribution has been observed to vary between 1.5 to 4.2 L/kg. Hydrochlorothiazide accumulates in red blood cells, so that whole blood levels are higher than those measured in plasma. Equilibrium between whole blood levels and plasma levels is reached 4 hours after oral administration. Hydrochlorothiazide crosses the placental barrier. Hydrochlorothiazide has a protein binding of 21 to 24%.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d0c108b4-f7b1-48a7-a88c-75fcd7f2d583"></a><a name="section-3.2.3.3"></a><p></p>
<h4>Metabolism and Excretion:</h4>
<p class="First">Hydrochlorothiazide is not metabolized. Hydrochlorothiazide is eliminated rapidly by the kidney. More than 60 percent of the oral dose is eliminated unchanged within 24 hours. When plasma levels have been followed for at least 24 hours, the plasma half-life has been observed to vary between 5.6 and 14.8 hours. The renal clearance has been observed to vary between 3.1 to 5.5 mL/min/kg.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_141e6851-9297-485b-88f8-1039061014b6"></a><a name="section-3.2.3.4"></a><p></p>
<h4>Special Populations:</h4>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_902d6c64-b8d3-4015-ab07-66bf529151d5"></a><a name="section-3.2.3.4.1"></a><p></p>
<h5>Decreased Renal Function:</h5>
<p class="First">In a study of patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> (mean creatinine clearance of 19 mL/min), the elimination half-life of hydrochlorothiazide was increased to 21 hours.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_cf5f6ea0-a4e7-4fb7-9166-916cab1208f6"></a><a name="section-3.2.3.4.2"></a><p></p>
<h5><span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">Pharmacokinetic Interactions</span> With Other Drugs:</h5>
<p class="First">Coadministration of propantheline or guanabenz increased the absorption of hydrochlorothiazide and coadministration of cholestyramine or colestipol decreased the absorption of hydrochlorothiazide.</p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="i4i_pharmacodynamics_id_dfe972b8-9406-41dd-96fb-efeda5d48ec4"></a><a name="section-3.3"></a><p></p>
<h2>Pharmacodynamics and Clinical Effect </h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_986eb8da-33f3-415e-97b7-313cf2cb0daf"></a><a name="section-3.3.1"></a><p></p>
<h3>Moexipril-Hydrochlorothiazide</h3>
<p class="First">In moexipril hydrochloride and hydrochlorothiazide clinical trials using moexipril doses of 3.75 to 30 mg and hydrochlorothiazide doses of 3.125 to 50 mg, the antihypertensive effects were sustained for at least 24 hours and they increased with increasing dose of either component. The extent of blood pressure reduction seen with moexipril hydrochloride and hydrochlorothiazide was approximately additive as compared to monotherapy of each component. The antihypertensive effects of moexipril hydrochloride and hydrochlorothiazide continue during therapy for up to 24 months. The effectiveness of moexipril hydrochloride and hydrochlorothiazide was not significantly influenced by patient age or gender. Although moexipril monotherapy is less effective in blacks than in nonblacks, the efficacy of moexipril hydrochloride and hydrochlorothiazide appears to be independent of race.</p>
<p>By blocking the renin-angiotensin-aldosterone axis, administration of moexipril tends to reduce the potassium loss associated with hydrochlorothiazide. In moexipril hydrochloride and hydrochlorothiazide controlled clinical trials, the average change in serum potassium was near zero in subjects who received 3.75 mg/6.25 mg or 7.5 mg/12.5 mg, but subjects who received 15 mg/12.5 mg or 15 mg/25 mg experienced a mild decrease in serum potassium, similar to that experienced by subjects who received the same dose of hydrochlorothiazide monotherapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_aac60abd-74c4-4def-b770-7b60d8e7d88a"></a><a name="section-3.3.2"></a><p></p>
<h3>Moexipril Hydrochloride</h3>
<p class="First">Single and multiple doses of 15 mg or more of moexipril give sustained inhibition of plasma ACE activity of 80 to 90%, beginning within 2 hours and lasting 24 hours (80%).</p>
<p>In controlled trials, the peak effects of orally administered moexipril increased with the dose administered over a dose range of 7.5 to 60 mg, given once a day. Antihypertensive effects were first detectable about 1 hour after dosing, with a peak effect between 3 and 6 hours after dosing. Just before dosing (i.e., at trough), the antihypertensive effects were less prominently related to dose and the antihypertensive effect tended to diminish during the 24-hour dosing interval when the drug was administered once a day. </p>
<p>In multiple-dose studies in the dose range of 7.5 to 30 mg once daily, moexipril lowered sitting blood pressure at trough by 4 to 11/3 to 6 mmHg more than placebo, a tendency toward increased response with higher doses. These effects are typical of ACE inhibitors; there are no trials of adequate size comparing moexipril with other antihypertensive agents.</p>
<p>Higher doses of moexipril generally leave a greater fraction of the peak blood pressure effect still present at trough. During dose titration, any decision as to the adequacy of a dosing regimen should be based on trough blood pressure measurements. If diastolic blood pressure control is not adequate at the end of the dosing interval, the dose can be increased or given as a divided (BID) regimen.</p>
<p>During chronic therapy, the antihypertensive effect of any dose of moexipril is generally evident within 2 weeks of treatment, with maximal reduction after 4 weeks. The antihypertensive effects of moexipril have been proven to continue during therapy for up to 24 months. </p>
<p>Moexipril, like other ACE inhibitors, is less effective in decreasing trough blood pressures in blacks than in nonblacks. Placebo-corrected trough group  diastolic blood pressure effects in blacks in the proposed dose range were +1 to -3 mmHg compared with responses in non-blacks of -4 to -6 mmHg.</p>
<p>The effectiveness of moexipril was not significantly influenced by patient age, gender, or weight. Moexipril has been shown to have antihypertensive activity in both pre- and postmenopausal women who have participated in placebo-controlled clinical trials.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_s34067-9"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE </h1>
<p class="First">Moexipril hydrochloride and hydrochlorothiazide tablets are indicated for treatment of patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. <span class="Bold">This fixed combination is not indicated for the initial therapy of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (see <a href="#i4i_dosage_admin_id_s34068-7">DOSAGE AND ADMINISTRATION</a>).</span></p>
<p>In using moexipril hydrochloride and hydrochlorothiazide tablets, consideration should be given to the fact that another ACE inhibitor, captopril, has caused <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, particularly in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> or collagen-vascular disease. Available data are insufficient to show that moexipril hydrochloride and hydrochlorothiazide tablets do not have a similar risk (see <span class="Bold"><a href="#i4i_section_id_af53ea13-467a-49b4-a753-301bc37f7fa7">WARNINGS, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span>/<span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span></a></span>). In addition, ACE inhibitors, for which adequate data are available, cause a higher rate of <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> in black than in nonblack patients (see <span class="Bold"><a href="#i4i_section_id_f61684a9-47e1-4767-a06f-c030ff2d4587">WARNINGS, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span></a></span>).</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_s34070-3"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS </h1>
<p class="First">Moexipril hydrochloride and hydrochlorothiazide tablets are contraindicated in patients who are hypersensitive to any component of this product and in patients with a history of <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> related to previous treatment with an ACE inhibitor. Because of the hydrochlorothiazide component, this product is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span> or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to other sulfonamide-derived drugs. <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> are more likely to occur in patients with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> or bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>.</p>
<p>Do not co-administer aliskiren with moexipril hydrochloride and hydrochlorothiazide in patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> (see <a href="#i4i_drug_interaction_id_ae606b66-e502-4c30-a1ae-808f46f40974">PRECAUTIONS, Drug Interactions</a>).</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_s34071-1"></a><a name="section-6"></a><p></p>
<h1>WARNINGS </h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1fa4257c-effd-432e-ad41-805071922d3f"></a><a name="section-6.1"></a><p></p>
<h2>Anaphylactoid and Possibly Related Reactions</h2>
<p class="First">Presumably because angiotensin-converting enzyme inhibitors affect the metabolism of eicosanoids and polypeptides, including endogenous bradykinin, patients receiving ACE inhibitors, including moexipril hydrochloride and hydrochlorothiazide, may be subject to a variety of adverse reactions, some of them serious. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e07d46c4-81b4-4f9b-a699-bfc69ef20fc2"></a><a name="section-6.1.1"></a><p></p>
<h3>Head and Neck <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span>: </h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span> involving the face, extremities, lips, tongue, glottis, and/or larynx has been reported in patients treated with ACE inhibitors, including moexipril. Symptoms suggestive of <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> or facial <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> occurred in &lt; 0.5% of moexipril-treated patients in placebo-controlled trials. None of the cases were considered life-threatening and all resolved either without treatment or with medication (antihistamines or glucocorticoids). One patient treated with hydrochlorothiazide alone experienced <span class="product-label-link" type="condition" conceptid="22350" conceptname="Edema of larynx">laryngeal edema</span>. No instances of <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> were reported in placebo-treated patients.</p>
<p>In cases of <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, treatment with moexipril hydrochloride and hydrochlorothiazide should be promptly discontinued and the patient carefully observed until the <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> disappears. In instances where <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> has been confined to the face and lips, the condition has generally resolved without treatment, although antihistamines have been useful in relieving symptoms.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span> associated with involvement of the tongue, glottis, or larynx may be fatal due to airway obstruction. Appropriate therapy, e.g., subcutaneous epinephrine solution 1:1000 (0.3 to 0.5 mL) and/or measures to ensure a patent airway, should be promptly provided</span> (see <span class="Bold"><a href="#i4i_adverse_effects_id_s34084-4">ADVERSE REACTIONS</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f61684a9-47e1-4767-a06f-c030ff2d4587"></a><a name="section-6.1.2"></a><p></p>
<h3>Intestinal <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span>:</h3>
<p class="First">Intestinal <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> has been reported in patients treated with ACE inhibitors. These patients presented with <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (with or without <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>); in some cases there was no prior history of facial <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> and C-1 esterase levels were normal. The <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> was diagnosed by procedures including abdominal CT scan or ultrasound, or at surgery, and symptoms resolved after stopping the ACE inhibitor. Intestinal <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> should be included in the differential diagnosis of patients on ACE inhibitors presenting with <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_207a1640-86ff-4e1b-872e-c7ae158721a6"></a><a name="section-6.1.3"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span> During Desensitization:</h3>
<p class="First">Two patients undergoing desensitizing treatment with hymenoptera venom while receiving ACE inhibitors sustained life-threatening <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>. In the same patients, these reactions did not occur when ACE inhibitors were temporarily withheld, but they reappeared when the ACE inhibitors were inadvertently readministered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_96d299dc-b813-414b-9849-6ae917c225e2"></a><a name="section-6.1.4"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span> During Membrane Exposure:</h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid reactions</span> have been reported in patients dialyzed with high-flux membranes and treated concomitantly with an ACE inhibitor. <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid reactions</span> have also been reported in patients undergoing low-density lipoprotein apheresis with dextran sulfate absorption. </p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c9315ac7-8dd2-464d-a956-cc80de2bcf98"></a><a name="section-6.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></h2>
<p class="First">Moexipril hydrochloride and hydrochlorothiazide can cause symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, although, as with other ACE inhibitors, this is unusual in uncomplicated hypertensive patients treated with moexipril hydrochloride and hydrochlorothiazide alone. Symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> is most likely to occur in patients who have been salt- and/or volume- depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. Volume- and/or salt-depletion should be corrected before initiating therapy with moexipril hydrochloride and hydrochlorothiazide (see <span class="Bold"><a href="#i4i_adverse_effects_id_s34084-4">ADVERSE REACTIONS</a></span>). </p>
<p>The thiazide component of moexipril hydrochloride and hydrochlorothiazide may potentiate the action of other antihypertensive drugs, especially ganglionic or peripheral adrenergic-blocking drugs. The antihypertensive effects of the thiazide component may also be enhanced in the postsympathectomy patient.</p>
<p>In patients with <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, with or without associated <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, ACE inhibitor therapy may cause excessive <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, which may be associated with <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span> or progressive <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span>, and rarely, with <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. In these patients, moexipril hydrochloride and hydrochlorothiazide therapy should be started under close medical supervision, and patients should be followed closely for the first two weeks of treatment and whenever the dose of moexipril hydrochloride and hydrochlorothiazide is increased. Care in avoiding <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> should also be taken in patients with <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">ischemic heart disease</span>, <span class="product-label-link" type="condition" conceptid="4189343" conceptname="Aortic valve stenosis">aortic stenosis</span>, or cerebrovascular disease, in whom an excessive decrease in blood pressure could result in a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> or a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">cerebrovascular accident</span>.</p>
<p>If <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occurs, the patient should be placed in a supine position and, if necessary, treated with an intravenous infusion of normal saline. Moexipril hydrochloride and hydrochlorothiazide treatment usually can be continued following restoration of blood pressure and volume.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c009dc2e-4bef-4abf-8ae9-df916eacffad"></a><a name="section-6.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></h2>
<p class="First">Moexipril hydrochloride and hydrochlorothiazide should be used with caution in patients with severe <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>. Thiazide diuretics may precipitate <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span> in such patients and the effects of repeated dosing may be cumulative.</p>
<p>As a consequence of inhibition of the renin-angiotensin-aldosterone system, changes in renal function may be anticipated in susceptible individuals. There is no clinical experience of moexipril hydrochloride and hydrochlorothiazide in the treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>.</p>
<p>Some hypertensive patients with no apparent preexisting renal vascular disease have developed increases in blood urea nitrogen and serum creatinine, usually minor and transient, especially when moexipril has been given concomitantly with a thiazide diuretic. This is more likely to occur in patients with preexisting <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. There may be a need for dose adjustment of moexipril hydrochloride and hydrochlorothiazide. <span class="Bold">Evaluation of hypertensive patients should always include assessment of renal function</span> (see <span class="Bold"><a href="#i4i_dosage_admin_id_s34068-7">DOSAGE AND ADMINISTRATION</a></span>).</p>
<p>In hypertensive patients with severe <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, whose renal function may depend on the activity of the renin-angiotensin-aldosterone system, treatment with ACE inhibitors, including moexipril, may be associated with <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span> and/or progressive <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span> and, rarely, <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> and/or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. </p>
<p>In hypertensive patients with unilateral or <span class="product-label-link" type="condition" conceptid="4118795" conceptname="Renal artery stenosis">bilateral renal artery stenosis</span>, increases in blood urea nitrogen and serum creatinine have been observed in some patients following ACE inhibitor therapy. These increases were almost always reversible upon discontinuation of the ACE inhibitor and/or diuretic therapy. In such patients, renal function should be monitored during the first few weeks of therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_af53ea13-467a-49b4-a753-301bc37f7fa7"></a><a name="section-6.4"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span>/<span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span></h2>
<p class="First">Another ACE inhibitor, captopril, has been shown to cause <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> and <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">bone marrow depression</span>, rarely in patients with <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">uncomplicated hypertension</span>, but more frequently in hypertensive patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, especially if they also have a collagen-vascular disease such as <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span> or <span class="product-label-link" type="condition" conceptid="134442" conceptname="Systemic sclerosis">scleroderma</span>. Although there were no instances of severe <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (absolute neutrophil count &lt; 500/mm<span class="Sup">3</span>) among patients given moexipril, as with other ACE inhibitors, monitoring of white blood cell counts should be considered for patients who have collagen-vascular disease, especially if the disease is associated with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Available data from clinical trials of moexipril are insufficient to show that moexipril does not cause <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> at rates similar to captopril.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_440e1731-3c7e-4a2a-9fbb-a39526afc69a"></a><a name="section-6.5"></a><p></p>
<h2>Fetal Toxicity </h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0cac282d-ad90-4e39-b197-f2127dbd1063"></a><a name="section-6.5.1"></a><p></p>
<h3>Pregnancy Category D </h3>
<p class="First">Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Resulting <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse events include skull hypoplasia, <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. When pregnancy is detected, discontinue moexipril hydrochloride and hydrochlorothiazide as soon as possible. These adverse outcomes are usually associated with use of these drugs in the second and third trimester of pregnancy. Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. Appropriate management of maternal <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> during pregnancy is important to optimize outcomes for both mother and fetus. </p>
<p>In the unusual case that there is no appropriate alternative to therapy with drugs affecting the renin-angiotensin system for a particular patient, apprise the mother of the potential risk to the fetus. Perform serial ultrasound examinations to assess the intra-amniotic environment. If <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> is observed, discontinue moexipril hydrochloride and hydrochlorothiazide, unless it is considered lifesaving for the mother. Fetal testing may be appropriate, based on the week of pregnancy. Patients and physicians should be aware, however, that <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> may not appear until after the fetus has sustained irreversible injury. Closely observe infants with histories of <span class="Italics">in utero </span>exposure to moexipril hydrochloride and hydrochlorothiazidefor <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, and <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> (see <a href="#i4i_pediatric_use_id_s34081-0">PRECAUTIONS, Pediatric Use</a>).</p>
<p>Intrauterine exposure to thiazide diuretics is associated with fetal or <span class="product-label-link" type="condition" conceptid="195064" conceptname="Perinatal jaundice due to hepatocellular damage">neonatal jaundice</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, and possibly other adverse reactions that have occurred in adults.</p>
<p>Reproduction studies with the combination of moexipril hydrochloride and hydrochlorothiazide (ratio 7.5:12.5) indicated that the combination possessed no teratogenic properties up to the lethal dose of 800 mg/kg/day in rats and up to the maternotoxic dose of 160 mg/kg/day in rabbits.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_94b99374-e764-44da-bed6-80a9e068c43f"></a><a name="section-6.6"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Failure</span></h2>
<p class="First">Rarely, ACE inhibitors have been associated with a syndrome that starts with <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span> and progresses to fulminant <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span> and sometimes <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. The mechanism of this syndrome is not understood. Patients receiving ACE inhibitors who develop <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical follow-up.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3900ec05-7277-447b-a056-6d72acacaed6"></a><a name="section-6.7"></a><p></p>
<h2>Impaired Hepatic Function</h2>
<p class="First">Moexipril hydrochloride and hydrochlorothiazide should be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte balance may precipitate <span class="product-label-link" type="condition" conceptid="377604" conceptname="Hepatic coma">hepatic coma</span>. In patients with mild to moderate cirrhosis given single 15 mg doses of moexipril, the C<span class="Sub">max</span> of moexipril was increased by about 50% and the AUC increased by about 120%, while the C<span class="Sub">max</span> for moexiprilat was decreased by about 50% and the AUC increased by almost 300%. No formal pharmacokinetic studies have been carried out with moexipril hydrochloride and hydrochlorothiazide in hypertensive patients with <span class="product-label-link" type="condition" conceptid="4326594" conceptname="Abnormal liver function">impaired liver function</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_cda408d1-a875-4492-89ce-df4801fbfb84"></a><a name="section-6.8"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">Systemic Lupus Erythematosus</span></h2>
<p class="First">Thiazide diuretics have been reported to cause exacerbation or activation of <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2d500607-76f6-42d4-ab12-71b20df03cd8"></a><a name="section-6.9"></a><p></p>
<h2>Acute <span class="product-label-link" type="condition" conceptid="379805" conceptname="Myopia">Myopia</span> and Secondary Angle-Closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span></h2>
<p class="First">Hydrochlorothiazide, a sulfonamide, can cause an idiosyncratic reaction, resulting in acute transient <span class="product-label-link" type="condition" conceptid="379805" conceptname="Myopia">myopia</span> and acute angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>. Symptoms include acute onset of decreased visual acuity or <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">ocular pain</span> and typically occur within hours to weeks of drug initiation. Untreated acute angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> can lead to permanent <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">vision loss</span>. The primary treatment is to discontinue hydrochlorothiazide as rapidly as possible. Prompt medical or surgical treatments may need to be considered if the intraocular pressure remains uncontrolled. Risk factors for developing acute angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> may include a history of sulfonamide or <span class="product-label-link" type="condition" conceptid="439224" conceptname="Drug allergy">penicillin allergy</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_s42232-9"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS </h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_c36d0fec-a529-428e-8a97-50e74975731f"></a><a name="section-7.1"></a><p></p>
<h2>General </h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c797dae7-8f22-4a0c-8858-deefd42e767f"></a><a name="section-7.1.1"></a><p></p>
<h3>Serum <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">Electrolyte Imbalances</span>:</h3>
<p class="First">In clinical trials with moexipril monotherapy, persistent <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> (serum potassium above 5.4 mEq/L) occurred in approximately 1.3% of hypertensive patients receiving moexipril. Risk factors for the development of <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> with ACE inhibitors include <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salt substitutes.</p>
<p>Treatment with thiazide diuretics has been associated with <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, and <span class="product-label-link" type="condition" conceptid="4289304" conceptname="Hypochloremic alkalosis">hypochloremic alkalosis</span>. These disturbances sometimes manifest as one or more of the following: dryness of mouth, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pains</span> or <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps</span>, muscular <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> has also been reported to sensitize or exaggerate the response of the heart to the toxic effects of digitalis. The risk of <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> is greatest in patients with cirrhosis of the liver, in patients experiencing a brisk <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>, in patients who are receiving inadequate oral intake of electrolytes, and in patients receiving concomitant therapy with corticosteroids or ACTH. </p>
<p>The opposite effects of moexipril and hydrochlorothiazide on serum potassium will approximately counterbalance each other in many patients, so that little net effect upon serum potassium will be seen. Initial and periodic determinations of serum electrolytes to detect possible <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span> should be performed at appropriate intervals.</p>
<p>Chloride deficits generally are mild and require specific treatment only under extraordinary circumstances (e.g., in liver disease or <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>). Dilutional <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> may occur in edematous patients; appropriate therapy is water restriction rather than administration of salt, except in rare instances when the <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> is life-threatening. In actual <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">salt depletion</span>, appropriate replacement is the therapy of choice.</p>
<p>Calcium excretion is reduced by thiazides. In a few patients on prolonged thiazide therapy, pathological changes in the parathyroid gland have been seen, with <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> and <span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">hypophosphatemia</span>. More serious complications of <span class="product-label-link" type="condition" conceptid="133729" conceptname="Hyperparathyroidism">hyperparathyroidism</span> (renal lithiasis, bone resorption, and <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulceration</span>) have not been seen. Thiazides enhance urinary excretion of magnesium and <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span> may result.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9f458fde-70c7-435c-a041-85433186066b"></a><a name="section-7.1.2"></a><p></p>
<h3>Other Metabolic Disturbances:</h3>
<p class="First">Thiazide diuretics may reduce glucose tolerance and may raise serum levels of <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, triglycerides, and uric acid. These effects are usually minor, but frank <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span> or overt <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> may be precipitated in susceptible patients. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_120c3b80-b7e1-4285-8d3a-254120b310ba"></a><a name="section-7.1.3"></a><p></p>
<h3>Surgery/Anesthesia:</h3>
<p class="First">In patients undergoing major surgery or during anesthesia with agents that produce <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, moexipril may block the effects of compensatory renin release. If <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occurs in this setting and is considered to be due to this mechanism, it can be corrected by volume expansion.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b322ddbc-5123-4e7c-a731-c9fbc711cf61"></a><a name="section-7.1.4"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span>:</h3>
<p class="First">Presumably due to the inhibition of the degradation of endogenous bradykinin, persistent nonproductive <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> has been reported with all ACE inhibitors, always resolving after discontinuation of therapy. ACE inhibitor-induced <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> should be considered in the differential diagnosis of <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>. In placebo-controlled trials with moexipril hydrochloride and hydrochlorothiazide, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> was present in 3% of moexipril hydrochloride and hydrochlorothiazide patients and 1% of patients given placebo.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_s34076-0"></a><a name="section-7.2"></a><p></p>
<h2>Information for Patients </h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e70138ab-02f2-40e0-a81d-f33b19fbe9a9"></a><a name="section-7.2.1"></a><p></p>
<h3>Food:</h3>
<p class="First">Patients should be advised to take moexipril hydrochloride and hydrochlorothiazide one hour before a meal (see <span class="Bold"><a href="#i4i_clinical_pharmacology_id_s34090-1">CLINICAL PHARMACOLOGY</a></span> and <span class="Bold"><a href="#i4i_dosage_admin_id_s34068-7">DOSAGE AND ADMINISTRATION</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8c7806c5-7669-4667-bd8e-5041861a78ca"></a><a name="section-7.2.2"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span>:</h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span>, including <span class="product-label-link" type="condition" conceptid="22350" conceptname="Edema of larynx">laryngeal edema</span>, may occur with treatment with ACE inhibitors, usually occurring early in therapy (within the first month). Patients should be so advised and told to report immediately any signs or symptoms suggesting <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> (<span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face, extremities, eyes, lips, tongue, difficulty in breathing) and to take no more drug until they have consulted with the prescribing physician.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_76493013-838c-445c-861c-e3da80af4ad3"></a><a name="section-7.2.3"></a><p></p>
<h3>Symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>:</h3>
<p class="First">Patients should be cautioned that <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span> can occur with moexipril hydrochloride and hydrochlorothiazide, especially during the first few days of therapy. If <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span> occurs, the patient should stop taking moexipril hydrochloride and hydrochlorothiazide and consult the prescribing physician.</p>
<p>All patients should be cautioned that excessive perspiration and <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> may lead to an excessive <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">fall in blood pressure</span> because of reduction in fluid volume. Other causes of <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">volume depletion</span> such as <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> may also lead to a <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">fall in blood pressure</span>; patients should be advised to consult their physician if they develop these conditions.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_575aabed-be60-4dbe-b1af-53bcd95d0c23"></a><a name="section-7.2.4"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span>:</h3>
<p class="First">Patients should be told not to use potassium supplements or salt substitutes containing potassium without consulting their physician.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8b2d0574-b680-4aeb-a8b8-d52ff6250858"></a><a name="section-7.2.5"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span>:</h3>
<p class="First">Patients should be told to report promptly any indication of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (e.g., <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>) that could be a sign of <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_22094046-4cfa-4c63-8cb1-4c4c8cd9cb6f"></a><a name="section-7.2.6"></a><p></p>
<h3>Pregnancy:</h3>
<p class="First">Female patients of childbearing age should be told about the consequences of exposure to moexipril hydrochloride and hydrochlorothiazide during pregnancy. Discuss treatment options with women planning to become pregnant. Patients should be asked to report pregnancies to their physicians as soon as possible.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_drug_interaction_id_ae606b66-e502-4c30-a1ae-808f46f40974"></a><a name="section-7.3"></a><p></p>
<h2>Drug Interactions </h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_dbbe4066-5055-4272-97a8-661f2ccd44e7"></a><a name="section-7.3.1"></a><p></p>
<h3>Potassium Supplements and Potassium-Sparing Diuretics:</h3>
<p class="First">As noted above (Serum <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">Electrolyte Imbalances</span>), the net effect of moexipril hydrochloride and hydrochlorothiazide may be to elevate a patient’s serum potassium, to reduce it, or to leave it unchanged. Potassium-sparing diuretics (spironolactone, amiloride, triamterene) or potassium supplements can increase the risk of <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>. If concomitant use of such agents is indicated, they should be given with caution, and the patient’s serum potassium should be monitored.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b7fc8fb0-3b2b-4c69-8901-42ab830f4e68"></a><a name="section-7.3.2"></a><p></p>
<h3>Oral Anticoagulants:</h3>
<p class="First">Interaction studies with warfarin failed to identify any clinically important effect of moexipril monotherapy on the serum concentrations of the anticoagulant or on its anticoagulant effect.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b1ce4975-f253-421f-a5b5-19a96f4a482f"></a><a name="section-7.3.3"></a><p></p>
<h3>Lithium:</h3>
<p class="First">Increased serum lithium levels and symptoms of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span> have been reported in patients receiving ACE inhibitors during therapy with lithium. Because renal clearance of lithium is reduced by thiazides, the risk of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span> is presumably raised further when, as in therapy with moexipril hydrochloride and hydrochlorothiazide, a thiazide diuretic is coadministered with the ACE inhibitor. These drugs should be coadministered with caution, and frequent monitoring of serum lithium levels is recommended.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_27c2b7a6-83c2-4ceb-a138-e4f9b93d8ff1"></a><a name="section-7.3.4"></a><p></p>
<h3>Gold: </h3>
<p class="First">Nitritoid reactions (symptoms include facial flusing, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>) have been reported rarely in patients on therapy with injectable gold (sodium aurothiomalate) and concomitant ACE inhibitor therapy including moexipril hydrochloride and hydrochlorothiazide.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ef7566d9-5dac-484e-907b-4849b11d3898"></a><a name="section-7.3.5"></a><p></p>
<h3>Alcohol, Barbiturates, or Narcotics:</h3>
<p class="First">Potentiation of <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> may occur in patients on thiazide diuretic therapy with concomitant use of alcohol, barbiturates, or narcotics.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_39a9f6fb-f221-4480-a8e8-0cd56261f5a5"></a><a name="section-7.3.6"></a><p></p>
<h3>Antidiabetic Agents:</h3>
<p class="First">Use of thiazide diuretics concomitantly with antidiabetic agents (oral agents and insulin) may require dosage adjustment of the antidiabetic agent. Moexipril has been used in clinical trials concomitantly with oral hypoglycemic agents and there was no evidence of any clinically important adverse interactions.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d22bed59-faa2-4844-b2be-de8731e8efb1"></a><a name="section-7.3.7"></a><p></p>
<h3>Cholestyramine and Colestipol Resins:</h3>
<p class="First">Absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins. Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85% and 43%, respectively.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_dac8a92f-d9e5-4db5-9028-533e0acf013b"></a><a name="section-7.3.8"></a><p></p>
<h3>Corticosteroids, ACTH:</h3>
<p class="First">Use of thiazide diuretics concomitantly with corticosteroids or ACTH may intensify <span class="product-label-link" type="condition" conceptid="4077438" conceptname="Electrolyte depletion">electrolyte depletion</span>, particularly <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7c2399bf-ed82-4174-81bd-3b5c773fc3c0"></a><a name="section-7.3.9"></a><p></p>
<h3>Pressor Amines:</h3>
<p class="First">Thiazide diuretics may decrease arterial responsiveness to pressor amines (e.g. norepinephrine), but not enough to preclude effectiveness of the pressor agent for therapeutic use.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d41bd4fa-473a-4f4f-a27f-d279798362e7"></a><a name="section-7.3.10"></a><p></p>
<h3>Skeletal Muscle Relaxants, Nondepolarizing:</h3>
<p class="First">Thiazide diuretics may increase the responsiveness to tubocurarine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b20e14c2-b002-415e-b85a-56f9b3e99392"></a><a name="section-7.3.11"></a><p></p>
<h3>Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors): </h3>
<p class="First">In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of NSAIDS, including selective COX-2 inhibitors, with ACE inhibitors, including moexipril, may result in deterioration of renal function, including possible <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>. These effects are usually reversible. Monitor renal function periodically in patients receiving moexipril and NSAID therapy. </p>
<p>The antihypertensive effect of ACE inhibitors and hydrochlorothiazide, as well as the diuretic and natriuretic effects of hydrochlorothiazide, may be attenuated by NSAIDS.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_cf8d9db4-1c26-45dd-b830-f754a290ee25"></a><a name="section-7.3.12"></a><p></p>
<h3>Dual Blockade of the Renin-Angiotensin System (RAS): </h3>
<p class="First">Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, and changes in renal function (including <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>) compared to monotherapy. Closely monitor blood pressure, renal function and electrolytes in patients on moexipril hydrochloride and hydrochlorothiazide and other agents that affect the RAS. </p>
<p>Do not co-administer aliskiren with moexipril hydrochloride and hydrochlorothiazide in patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. Avoid use of aliskiren with moexipril hydrochloride and hydrochlorothiazide<span class="Sup"></span>in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (GFR &lt;60 mL/min) </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7fe354ce-bb31-41c7-8766-ad91f84ae7b2"></a><a name="section-7.3.13"></a><p></p>
<h3>Other Agents:</h3>
<p class="First">No clinically important <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interactions</span> occurred when moexipril was administered concomitantly with digoxin or cimetidine.</p>
<p>Moexipril has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H<span class="Sub">2</span> blockers, digoxin, and <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>-lowering agents. There was no evidence of clinically important adverse interactions. In general, ACE inhibitors have less than additive effects with beta-adrenergic blockers, presumably because both work by inhibiting the renin-angiotensin system.</p>
<p>Coadministration of propantheline or guanabenz increased the absorption of hydrochlorothiazide. </p>
</div>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_s34083-6"></a><a name="section-7.4"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility </h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c9675ec4-4011-4552-b49e-f546a6133f2b"></a><a name="section-7.4.1"></a><p></p>
<h3>Moexipril Hydrochloride</h3>
<p class="First">No evidence of carcinogenicity was detected in long-term studies when moexipril was administered to mice and rats at doses up to 14 or 27.3 times the Maximum Recommended Human Dose (MRHD) on a mg/m<span class="Sup">2</span> basis. No mutagenicity was detected in the Ames test and microbial reverse mutation assay, with and without metabolic activation, or in an <span class="Italics">in vivo</span> nucleus anomaly test. However, increased chromosomal aberration frequency in Chinese hamster ovary (CHO) cells was detected under metabolic activation conditions at a 20-hour harvest time. Reproduction studies have been performed in rabbits at oral doses up to 0.7 times the MRHD on a mg/m<span class="Sup">2</span> basis, and in rats up to 90.9 times the MRHD on a mg/m<span class="Sup">2</span> basis. No indication of impaired fertility, reproductive toxicity, or <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> was observed. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_78d48c1d-2d28-46a3-a9c7-2faf04612fb5"></a><a name="section-7.4.2"></a><p></p>
<h3>Hydrochlorothiazide</h3>
<p class="First">Under the auspices of the National Toxicology Program, rats and mice received hydrochlorothiazide in their feed for two years, at doses up to 600 mg/kg/day in mice and up to 100 mg/kg/day in rats. These studies uncovered no evidence of a carcinogenic potential of hydrochlorothiazide in rats or female mice, but there was equivocal evidence of hepatocarcinogenicity in male mice. Hydrochlorothiazide was not genotoxic in <span class="Italics">in vitro</span> assays using <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> TA 98, TA 100, TA 1535, TA 1537, and TA 1538 of <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> typhimurium</span> (the Ames test); in the CHO test for chromosomal aberrations; or in <span class="Italics">in vivo</span> assays using mouse germinal cell chromosomes, Chinese hamster bone marrow chromosomes; and the <span class="Italics">Drosophila</span> sex-linked recessive lethal trait gene. Positive test results were obtained in the <span class="Italics">in vitro</span> CHO Sister Chromatid Exchange (clastogenicity) test and in the Mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span> Cell (mutagenicity) assays, using concentrations of hydrochlorothiazide of 43 to 1300 mcg/mL. Positive test results were also obtained in the <span class="Italics">Aspergillus nidulans</span> nondisjunction assay, using an unspecified concentration of hydrochlorothiazide.</p>
<p>Hydrochlorothiazide had no adverse effects on the fertility of mice and rats of either sex in studies wherein these species were exposed, via their diets, to doses up to 100 and 4 mg/kg/day, respectively, prior to mating and throughout gestation.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_s34080-2"></a><a name="section-7.5"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether moexipril or moexiprilat is excreted in human milk. Thiazides are excreted in human milk. Because of the potential for serious adverse reactions in nursing infants from hydrochlorothiazide and the unknown effects of moexipril or moexiprilat in infants, a decision should be made whether to discontinue nursing or to discontinue moexipril hydrochloride and hydrochlorothiazide, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_s34081-0"></a><a name="section-7.6"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First"><span class="Underline">Neonates with a history of <span class="Italics">in utero </span>exposure to moexipril hydrochloride and hydrochlorothiazide</span>: </p>
<p>If <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span> or <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occurs, direct attention toward support of blood pressure and renal perfusion. Exchange transfusions or dialysis may be required as a means of reversing <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and/or substituting for disordered renal function.</p>
<p>Safety and effectiveness of moexipril hydrochloride and hydrochlorothiazide in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_s34082-8"></a><a name="section-7.7"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Of the patients who received moexipril hydrochloride and hydrochlorothiazide in controlled clinical studies, 24% were 65 years of age or older. No overall differences in effectiveness or safety were observed between these patients and younger patients. In elderly patients receiving moexipril, plasma levels of drug are slightly higher and renal clearance is reduced when compared to younger patients, but these effects did not have detectable consequences. Hydrochlorothiazide is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_s34084-4"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS </h1>
<p class="First">Moexipril hydrochloride and hydrochlorothiazide has been evaluated for safety in more than 1140 patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> with more than 120 treated for more than one year. Moexipril hydrochloride and hydrochlorothiazide has not demonstrated a potential for causing adverse experiences different from those previously associated with other ACE inhibitor/diuretic combinations. The overall incidence of reported adverse events was slightly less in patients treated with moexipril hydrochloride and hydrochlorothiazide than patients treated with placebo.</p>
<p>Adverse experiences were usually mild and transient, and there was no relationship between adverse experiences and gender, race, age, or total daily dosage (except for serum potassium decreases at 50 mg hydrochlorothiazide) within the moexipril/hydrochlorothiazide dosage range of 3.75 mg/3.125 mg to 30 mg/50 mg. Discontinuation of therapy due to adverse experiences was required in 5.3% of patients treated with moexipril hydrochloride and hydrochlorothiazide and in 8.4% of patients treated with placebo. The most common reasons for discontinuation of therapy with moexipril hydrochloride and hydrochlorothiazide were <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> (0.5%) and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (0.5%).</p>
<p>All adverse experiences considered at least possibly related to treatment that occurred at any dose in placebo-controlled trials of once-daily dosing in more than 1% of patients treated with moexipril hydrochloride and hydrochlorothiazide and that were at least as frequent in the moexipril hydrochloride and hydrochlorothiazide group as in the placebo group are shown in the following table.</p>
<a name="_RefIDD51E0664189543D992D4922A52B0F646"></a><table>
<caption><span>Adverse Events in Placebo-Controlled Trials </span></caption>
<col width="22%">
<col width="44%">
<col width="18%">
<tbody class="Headless">
<tr class="First">
<td class="Lrule Toprule" valign="top"><p class="First"><span class="Bold">ADVERSE EVENT</span></p></td>
<td class="Lrule Toprule" valign="top">
<p class="First"><span class="Bold">MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE </span></p>
<p><span class="Bold">(N=506)</span></p>
<p><span class="Bold"> N (%)</span></p>
</td>
<td class="Toprule" valign="top">
<p class="First"><span class="Bold">PLACEBO </span></p>
<p><span class="Bold">(N=202) </span></p>
<p><span class="Bold">N (%</span>)</p>
</td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></p></td>
<td class="Lrule" valign="top"><p class="First">15 (3)</p></td>
<td valign="top"><p class="First">2 (1)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></p></td>
<td class="Lrule" valign="top"><p class="First">7 (1.4)</p></td>
<td valign="top"><p class="First">2 (1)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></p></td>
<td class="Botrule Lrule" valign="top"><p class="First">5 (1)</p></td>
<td class="Botrule" valign="top"><p class="First">1 (0.5)</p></td>
</tr>
</tbody>
</table>
<p>Other adverse experiences occurring in more than 1% of patients treated with moexipril hydrochloride and hydrochlorothiazide in controlled or uncontrolled trials, some of which were of uncertain drug relationship, listed in decreasing frequency include: <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory infection</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">flu syndrome</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, <span class="product-label-link" type="condition" conceptid="320536" conceptname="Electrocardiogram abnormal">abnormal ECG</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, increased SGPT, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>, <span class="product-label-link" type="condition" conceptid="4167328" conceptname="Pyuria">pyuria</span>, <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>, and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>. See <span class="Bold"><a href="#i4i_warnings_id_s34071-1">WARNINGS</a></span> and <span class="Bold"><a href="#i4i_precautions_id_s42232-9">PRECAUTIONS</a></span> for discussion of <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>/<span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, fetal/neonatal morbidity and mortality, serum <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalances</span>, and <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>.</p>
<p>The following adverse experiences, some of which are of uncertain drug relationship, were reported in moexipril hydrochloride and hydrochlorothiazide controlled or uncontrolled clinical trials in less than 1% of patients or have been attributed to other ACE inhibitors. Within each organ system, adverse experiences are listed in decreasing frequency. </p>
<p><span class="Italics">Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">Palpitation</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarct</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>, first degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span>, <span class="product-label-link" type="condition" conceptid="4008580" conceptname="Ventricular bigeminy">ventricular extrasystoles</span>, <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">sinus bradycardia</span>, <span class="product-label-link" type="condition" conceptid="316429" conceptname="Premature beats">bigeminy</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="313791" conceptname="Bundle branch block">bundle branch block</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">heart arrest</span>, <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span>, <span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">peripheral vascular disorder</span>, prolonged QT interval, inverted T wave, <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span>.</p>
<p><span class="Italics">Dermatologic:</span> <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">Eczema</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span>, herpes simplex, <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">contact dermatitis</span>, <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span>, <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="140176" conceptname="Erythema nodosum">erythema nodosum</span>, <span class="product-label-link" type="condition" conceptid="137213" conceptname="Dermal mycosis">fungal dermatitis</span>, <span class="product-label-link" type="condition" conceptid="4220002" conceptname="Furuncle">furunculosis</span>, <span class="product-label-link" type="condition" conceptid="4083795" conceptname="Maculopapular eruption">maculopapular rash</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpuric rash</span>, skin carcinoma, <span class="product-label-link" type="condition" conceptid="4042856" conceptname="Fibrous nodule">subcutaneous nodule</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="135338" conceptname="Pemphigus">pemphigus</span>.</p>
<p><span class="Italics">Gastrointestinal:</span> <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>, <span class="product-label-link" type="condition" conceptid="4103655" conceptname="Dental abscess">periodontal abscess</span>, <span class="product-label-link" type="condition" conceptid="4098112" conceptname="Biliary sludge">cholelithiasis</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="4281516" conceptname="Gingivitis">gingivitis</span>, <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="133228" conceptname="Dental caries">tooth caries</span>, <span class="product-label-link" type="condition" conceptid="4301764" conceptname="Cheilitis">cheilitis</span>, <span class="product-label-link" type="condition" conceptid="201773" conceptname="Enteritis of small intestine">enteritis</span>, <span class="product-label-link" type="condition" conceptid="4152350" conceptname="Burping">eructation</span>, gastrointestinal carcinoma, <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">glossitis</span>, <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">increased appetite</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>, <span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, <span class="product-label-link" type="condition" conceptid="4217621" conceptname="Black hairy tongue">tongue discoloration</span>, <span class="product-label-link" type="condition" conceptid="4217627" conceptname="Edema of the tongue">tongue edema</span>.</p>
<p><span class="Italics">Hematologic:</span> <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span>, <span class="product-label-link" type="condition" conceptid="4195171" conceptname="Normocytic hypochromic anemia">hypochromic anemia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, abnormal erythrocytes, <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymosis</span>, <span class="product-label-link" type="condition" conceptid="320074" conceptname="Lymphocytosis">lymphocytosis</span>, <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span>, <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">petechia</span>, abnormal WBC, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>.</p>
<p><span class="Italics">Metabolic</span>: <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipemia</span>, increased <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>, <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span>, <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">bilirubinemia</span>, increased creatinine, <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>, increased BUN, increased CPK, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, increased alkaline phosphatase, increased amylase, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, decreased glucose tolerance, <span class="product-label-link" type="condition" conceptid="135772" conceptname="Goiter">goiter</span>, <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span>, <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>, <span class="product-label-link" type="condition" conceptid="4016089" conceptname="Hypochloremia">hypochloremia</span>, <span class="product-label-link" type="condition" conceptid="4228222" conceptname="Hypoproteinemia">hypoproteinemia</span>, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>.</p>
<p><span class="Italics">Neurologic/Psychiatric:</span> <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span>, postural <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="444252" conceptname="Neuritis">neuritis</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypesthesia</span>, decreased libido, <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuralgia</span>, <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">amnesia</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="443454" conceptname="Cerebral infarction">cerebral infarct</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional lability</span>, <span class="product-label-link" type="condition" conceptid="374923" conceptname="Bell's palsy">facial paralysis</span>, <span class="product-label-link" type="condition" conceptid="4195475" conceptname="Behavior showing reduced motor activity">hypokinesia</span>, <span class="product-label-link" type="condition" conceptid="444243" conceptname="Neurosis">neurosis</span>, <span class="product-label-link" type="condition" conceptid="261599" conceptname="Vocal cord palsy">vocal cord paralysis</span>.</p>
<p><span class="Italics">Renal:</span> <span class="product-label-link" type="condition" conceptid="4168705" conceptname="Albuminuria">Albuminuria</span>, <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">urinary frequency</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, <span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">glycosuria</span>, <span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">cystitis</span>, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, <span class="product-label-link" type="condition" conceptid="40304526" conceptname="Nocturia">nocturia</span>, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">kidney calculus</span>, <span class="product-label-link" type="condition" conceptid="198199" conceptname="Pyelonephritis">pyelonephritis</span>, <span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">urate crystalluria</span>, <span class="product-label-link" type="condition" conceptid="442282" conceptname="Urinary casts">urinary casts</span>, <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>.</p>
<p><span class="Italics">Respiratory:</span> <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">Epistaxis</span>, <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, lung carcinoma, <span class="product-label-link" type="condition" conceptid="261687" conceptname="Hemoptysis">hemoptysis</span>, <span class="product-label-link" type="condition" conceptid="24969" conceptname="Laryngitis">laryngitis</span>, <span class="product-label-link" type="condition" conceptid="4142495" conceptname="Hypophonia">voice alteration</span>, eosinophilic <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span>.</p>
<p><span class="Italics">Urogenital:</span> <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">Vaginal hemorrhage</span>, breast carcinoma, <span class="product-label-link" type="condition" conceptid="4230799" conceptname="Edema of scrotum">scrotal edema</span>, <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span>, <span class="product-label-link" type="condition" conceptid="78474" conceptname="Hypertrophy of breast">breast enlargement</span>, <span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">breast pain</span>, <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">dysmenorrhea</span>, <span class="product-label-link" type="condition" conceptid="195873" conceptname="Leukorrhea">leukorrhea</span>.</p>
<p><span class="Italics">Other:</span> <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">arthrosis</span>, <span class="product-label-link" type="condition" conceptid="199860" conceptname="Hernia of abdominal cavity">hernia</span>, <span class="product-label-link" type="condition" conceptid="24134" conceptname="Neck pain">neck pain</span>, <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">cyst</span>, <span class="product-label-link" type="condition" conceptid="4195698" conceptname="Tenosynovitis">tenosynovitis</span>, <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">abnormal vision</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span>, <span class="product-label-link" type="condition" conceptid="435613" conceptname="Cellulitis">cellulitis</span>, <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">moniliasis</span>, <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span>, <span class="product-label-link" type="condition" conceptid="433778" conceptname="Orbital hemorrhage">eye hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span>, <span class="product-label-link" type="condition" conceptid="134453" conceptname="Bursitis">bursitis</span>, <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">deafness</span>, <span class="product-label-link" type="condition" conceptid="380733" conceptname="Otalgia">ear pain</span>, <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, <span class="product-label-link" type="condition" conceptid="4274964" conceptname="Iritis">iritis</span>, <span class="product-label-link" type="condition" conceptid="4228784" conceptname="Nuchal rigidity">neck rigidity</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>, <span class="product-label-link" type="condition" conceptid="4090255" conceptname="Retinal drusen">retinal degeneration</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>.</p>
<p>Monotherapy with moexipril has been evaluated for safety in over 3000 patients. In clinical trials, the observed adverse experiences with moexipril were similar to those seen in the moexipril hydrochloride and hydrochlorothiazide trials.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_765bb880-c02a-4f43-8dd0-8702f4462184"></a><a name="section-8.1"></a><p></p>
<h2>Hydrochlorothiazide</h2>
<p class="First">The following adverse reactions have been reported with hydrochlorothiazide and, within each organ system, are listed by decreasing severity.</p>
<p><span class="Italics">Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic hypotension</span> (may be potentiated by alcohol, barbiturates, or narcotics).</p>
<p><span class="Italics">Gastrointestinal:</span> <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> (intrahepatic cholestatic, see <span class="Bold"><a href="#i4i_warnings_id_s34071-1">WARNINGS</a></span>), <span class="product-label-link" type="condition" conceptid="29056" conceptname="Sialoadenitis">sialadenitis</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, cramping, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4002232" conceptname="Epigastric discomfort">gastric irritation</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>.</p>
<p><span class="Italics">Neurologic/Psychiatric:</span> <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">Vertigo</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, transient <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4168789" conceptname="Xanthopsia">xanthopsia</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>.</p>
<p><span class="Italics">Musculoskeletal:</span> <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Muscle spasm</span>.</p>
<p><span class="Italics">Hematologic:</span> <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">Aplastic anemia</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>.</p>
<p><span class="Italics">Metabolic:</span> <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">glycosuria</span>, <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span>.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>: </span> Necrotizing <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">angiitis</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span> including <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span> and <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>. </p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="i4i_lab_tests_id_s34075-2"></a><a name="section-8.2"></a><p></p>
<h2>Clinical Laboratory Test Findings </h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0aad73ea-9705-4c2d-92b1-95182883605e"></a><a name="section-8.2.1"></a><p></p>
<h3>Serum Electrolytes:</h3>
<p class="First">See <span class="Bold"><a href="#i4i_precautions_general_id_c36d0fec-a529-428e-8a97-50e74975731f">PRECAUTIONS, General</a></span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c1838af9-0aaf-42d3-9edf-8c6899f06ea8"></a><a name="section-8.2.2"></a><p></p>
<h3>Creatinine and Blood Urea Nitrogen: </h3>
<p class="First">As with other ACE inhibitors, minor increases in blood urea nitrogen or serum creatinine, reversible upon discontinuation of therapy, were observed in less than 1% of patients with <span class="product-label-link" type="condition" conceptid="320128" conceptname="Essential hypertension">essential hypertension</span> who were treated with moexipril hydrochloride and hydrochlorothiazide. Increases are more likely to occur in patients with compromised renal function (see <span class="Bold"><a href="#i4i_precautions_general_id_c36d0fec-a529-428e-8a97-50e74975731f">PRECAUTIONS, General</a></span>). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_922e22b6-b26f-454d-a6f4-2283fcea4947"></a><a name="section-8.2.3"></a><p></p>
<h3>Other (causal relationship unknown):</h3>
<p class="First">Clinically important changes in standard laboratory tests were rarely associated with moexipril hydrochloride and hydrochlorothiazide administration.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_s34088-5"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE </h1>
<p class="First">No specific information is available on the treatment of overdosage with moexipril hydrochloride and hydrochlorothiazide. Treatment should be symptomatic and supportive. Therapy with moexipril hydrochloride and hydrochlorothiazide should be discontinued and the patient observed closely. Suggested measures include induction of <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> and/or gastric lavage and correction of <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span> and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> by established procedures.</p>
<p>Single oral doses of 2 g/kg moexipril were associated with significant lethality in mice. Rats, however, tolerated single oral doses of up to 3 g/kg. The oral LD<span class="Sub">50</span> of hydrochlorothiazide is greater than 10 g/kg in mice and rats. For the combination of moexipril hydrochloride and hydrochlorothiazide (ratio 7.5:12.5), the approximate LD<span class="Sub">50</span> was around 10 g/kg for mice and above 10 g/kg for rats. Addition of hydrochlorothiazide to moexipril hydrochloride did not increase the acute toxicity due to moexipril hydrochloride.</p>
<p>Human <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> of moexipril have not been reported. In case reports of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> with other ACE inhibitors, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> has been the principal adverse effect noted. The most common signs and symptoms observed with an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of hydrochlorothiazide have been those of <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> and <span class="product-label-link" type="condition" conceptid="4077438" conceptname="Electrolyte depletion">electrolyte depletion</span> (<span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="4016089" conceptname="Hypochloremia">hypochloremia</span>, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>). If digitalis has also been administered, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> may accentuate <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>.</p>
<p>No data are available to suggest that physiological maneuvers (e.g., maneuvers to change the pH of the urine) would accelerate elimination of moexipril and its metabolites. The dialyzability of moexipril is not known.</p>
<p>Angiotensin II could presumably serve as a specific antagonist-antidote in the setting of moexipril <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, but angiotensin II is essentially unavailable outside of research facilities. Because the hypotensive effect of moexipril is achieved through vasodilation and effective <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">hypovolemia</span>, it is reasonable to treat moexipril <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> by infusion of normal saline solution. In addition, renal function and serum potassium should be monitored.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_s34068-7"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION </h1>
<p class="First">Moexipril and hydrochlorothiazide are effective treatments for <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. The recommended dosage range of moexipril is 7.5 to 30 mg daily, administered in a single or two divided doses one hour before meals, while hydrochlorothiazide is effective in a dosage of 12.5 to 50 mg daily.</p>
<p>The side effects (see <span class="Bold"><a href="#i4i_warnings_id_s34071-1">WARNINGS</a></span>) of moexipril are generally rare and apparently independent of dose; those of hydrochlorothiazide are a mixture of dose-dependent phenomena (primarily <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>) and dose-independent phenomena (e.g., <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>), the former much more common than the latter. Therapy with any combination of moexipril and hydrochlorothiazide will be associated with both sets of dose-independent side effects, but regimens in which moexipril is combined with low doses of hydrochlorothiazide produce minimal effects on serum potassium. In moexipril hydrochloride and hydrochlorothiazide tablets controlled clinical trials, the average change in serum potassium was near zero in subjects who received 3.75 mg/6.25 mg or 7.5 mg/12.5 mg, but subjects who received 15 mg/12.5 mg or 15 mg/25 mg experienced a mild decrease in serum potassium, similar to that experienced by subjects who received the same dose of hydrochlorothiazide monotherapy. To minimize dose-independent side effects, it is usually appropriate to begin combination therapy only after a patient has failed to achieve the desired effect with monotherapy.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5ba7a077-a954-458c-959f-1a16b63a500a"></a><a name="section-10.1"></a><p></p>
<h2>Dose Titration Guided by Clinical Effect:</h2>
<p class="First">A patient whose blood pressure is not adequately controlled with either moexipril or hydrochlorothiazide monotherapy may be given moexipril hydrochloride and hydrochlorothiazide tablets 7.5 mg/12.5 mg, moexipril hydrochloride and hydrochlorothiazide tablets 15 mg/12.5 mg or moexipril hydrochloride and hydrochlorothiazide tablets 15 mg/25 mg one hour before a meal. Further increases of moexipril, hydrochlorothiazide or both depend on clinical response. The hydrochlorothiazide dose should generally not be increased until 2 to 3 weeks have elapsed.</p>
<p>Total daily doses above 30 mg/50 mg a day have not been studied in hypertensive patients. Patients whose blood pressures are adequately controlled with 25 mg of hydrochlorothiazide daily, but who experience significant potassium loss with this regimen, may achieve blood pressure control without <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte disturbance</span> if they are switched to moexipril 3.75 mg/hydrochlorothiazide 6.25 mg (one-half of the moexipril hydrochloride and hydrochlorothiazide 7.5 mg/12.5 mg tablet). For patients who experience an excessive reduction in blood pressure with moexipril hydrochloride and hydrochlorothiazide tablets 7.5 mg/12.5 mg, the physician may consider prescribing moexipril 3.75 mg/hydrochlorothiazide 6.25 mg.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_183a8c87-efbf-4b39-8a28-b041cb59d4f9"></a><a name="section-10.2"></a><p></p>
<h2>Replacement Therapy:</h2>
<p class="First">The combination may be substituted for the titrated individual active ingredients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_000b26a0-286b-4fdb-a0e4-8f4df8b5db66"></a><a name="section-10.3"></a><p></p>
<h2>Use in <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>:</h2>
<p class="First">The usual dosage regimen of moexipril hydrochloride and hydrochlorothiazide tablets does not need to be adjusted as long as the patient’s creatinine clearance is &gt; 40 mL/min/1.73 m<span class="Sup">2</span> (serum creatinine approximately ≤ 3 mg/dL or 265 μmol/L). In patients with more severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, loop diuretics are preferred to thiazides, so moexipril hydrochloride and hydrochlorothiazide tablets are not recommended (see <span class="Bold"><a href="#i4i_precautions_general_id_c36d0fec-a529-428e-8a97-50e74975731f">PRECAUTIONS, General</a></span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_s34069-5"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Moexipril hydrochloride and hydrochlorothiazide tablets 7.5 mg/12.5 mg are yellow colored, oval shaped, biconvex, film-coated tablets with 'G' and breakline engraved on one side and ‘207’ engraved on the other side. They are supplied as follows:</p>
<p>Bottles of 30 NDC 68462-207-30<br>Bottles of 100 NDC 68462-207-01<br>Bottles of 1000 NDC 68462-207-10 </p>
<p>Moexipril hydrochloride and hydrochlorothiazide tablets 15 mg/12.5 mg are white colored, oval shaped, biconvex, film-coated tablets with ‘G' and breakline engraved on one side and ‘206’ engraved on the other side. They are supplied as follows: </p>
<p>Bottles of 30 NDC 68462-206-30<br>Bottles of 100 NDC 68462-206-01<br>Bottles of 1000 NDC 68462-206-10 </p>
<p>Moexipril hydrochloride and hydrochlorothiazide tablets 15 mg/25 mg are yellow colored, oval shaped, biconvex, film-coated tablets with ‘G' and breakline engraved on one side and ‘205’ engraved on the other side. They are supplied as follows:</p>
<p>Bottles of 30 NDC 68462-205-30<br>Bottles of 100 NDC 68462-205-01<br>Bottles of 1000 NDC 68462-205-10 </p>
<div class="Section" data-sectionCode="44425-7">
<a name="i4i_storage_id_d69390f9-4b9f-4ae6-a4a8-710af729e1da"></a><a name="section-11.1"></a><p></p>
<p class="First">Store, tightly closed, at 20° to 25° C (68° to 77° F) [See USP Controlled Room Temperature]. Protect from excessive moisture.</p>
<p>If product package is subdivided, dispense in tight containers as described in USP-NF.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_55a68d26-d001-4a4a-9d6a-da731cd5fa61"></a><a name="section-12"></a><p></p>
<p class="First">Manufactured by:</p>
<p><span class="Bold">Glenmark Generics Ltd.</span><br>Colvale-Bardez, Goa 403 513, India </p>
<p>Manufactured for:<br><a name="id1065"></a><img alt="Glenmark logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e71002c8-3463-4950-b984-c4eee356a5f2&amp;name=30b478aa-eb7f-4a97-9cd0-edfc0f368e7a-03.jpg"></p>
<p><span class="Bold">Glenmark Generics Inc., USA</span><br>Mahwah, NJ 07430</p>
<p>Questions? 1 (888)721-7115</p>
<p>www.glenmarkgenerics.com</p>
<p>January 2013</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_cdde4327-eea9-4c73-b470-91c13174c783"></a><a name="section-13"></a><p></p>
<h1>Principal Display Panel - 7.5 mg/12.5 mg</h1>
<div class="Figure">
<a name="id1075"></a><img alt="7.5 mg/12.5 mg Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e71002c8-3463-4950-b984-c4eee356a5f2&amp;name=30b478aa-eb7f-4a97-9cd0-edfc0f368e7a-04.jpg">
</div>
<p class="First"><span class="Bold">Glenmark</span><br><span class="Bold">NDC 68462-207-01</span><br><span class="Bold">MOEXIPRIL HCl</span><br><span class="Bold">AND</span><br><span class="Bold">HYDROCHLOROTHIAZIDE</span><br><span class="Bold">TABLETS</span><br><span class="Bold">7.5 mg / 12.5 mg</span><br><span class="Bold">Rx only     100 Tablets</span></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_1503f9f9-2793-4fa0-b504-eb5359a2a49d"></a><a name="section-14"></a><p></p>
<h1>Principal Display Panel - 15 mg/12.5 mg</h1>
<div class="Figure">
<a name="id1088"></a><img alt="15 mg/12.5 mg Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e71002c8-3463-4950-b984-c4eee356a5f2&amp;name=30b478aa-eb7f-4a97-9cd0-edfc0f368e7a-05.jpg">
</div>
<p class="First"><span class="Bold">Glenmark</span><br><span class="Bold">NDC 68462-206-01</span><br><span class="Bold">MOEXIPRIL HCl</span><br><span class="Bold">AND</span><br><span class="Bold">HYDROCHLOROTHIAZIDE</span><br><span class="Bold">TABLETS</span><br><span class="Bold">15 mg / 12.5 mg</span><br><span class="Bold">Rx only     100 Tablets</span></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_c7702948-d243-4038-8eaf-afe93800dfd4"></a><a name="section-15"></a><p></p>
<h1>Principal Display Panel - 15 mg/25 mg</h1>
<div class="Figure">
<a name="id1101"></a><img alt="15 mg/25 mg Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e71002c8-3463-4950-b984-c4eee356a5f2&amp;name=30b478aa-eb7f-4a97-9cd0-edfc0f368e7a-06.jpg">
</div>
<p class="First"><span class="Bold">Glenmark</span><br><span class="Bold">NDC 68462-205-01</span><br><span class="Bold">MOEXIPRIL HCl</span><br><span class="Bold">AND</span><br><span class="Bold">HYDROCHLOROTHIAZIDE</span><br><span class="Bold">TABLETS</span><br><span class="Bold">15 mg / 25 mg</span><br><span class="Bold">Rx only     100 Tablets</span></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE 		
					</strong><br><span class="contentTableReg">moexipril hydrochloride and hydrochlorothiazide tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:68462-207</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>MOEXIPRIL HYDROCHLORIDE</strong> (MOEXIPRILAT) </td>
<td class="formItem">MOEXIPRIL HYDROCHLORIDE</td>
<td class="formItem">7.5 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>HYDROCHLOROTHIAZIDE</strong> (HYDROCHLOROTHIAZIDE) </td>
<td class="formItem">HYDROCHLOROTHIAZIDE</td>
<td class="formItem">12.5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM OXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE (TYPE H)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 6000</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (biconvex) </td>
<td class="formLabel">Size</td>
<td class="formItem">11mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">G;207</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:68462-207-30</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:68462-207-01</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:68462-207-10</td>
<td class="formItem">1000  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA090718</td>
<td class="formItem">03/18/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE 		
					</strong><br><span class="contentTableReg">moexipril hydrochloride and hydrochlorothiazide tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:68462-206</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>MOEXIPRIL HYDROCHLORIDE</strong> (MOEXIPRILAT) </td>
<td class="formItem">MOEXIPRIL HYDROCHLORIDE</td>
<td class="formItem">15 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>HYDROCHLOROTHIAZIDE</strong> (HYDROCHLOROTHIAZIDE) </td>
<td class="formItem">HYDROCHLOROTHIAZIDE</td>
<td class="formItem">12.5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM OXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE (TYPE H)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 6000</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (biconvex) </td>
<td class="formLabel">Size</td>
<td class="formItem">13mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">G;206</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:68462-206-30</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:68462-206-01</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:68462-206-10</td>
<td class="formItem">1000  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA090718</td>
<td class="formItem">03/18/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE 		
					</strong><br><span class="contentTableReg">moexipril hydrochloride and hydrochlorothiazide tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:68462-205</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>MOEXIPRIL HYDROCHLORIDE</strong> (MOEXIPRILAT) </td>
<td class="formItem">MOEXIPRIL HYDROCHLORIDE</td>
<td class="formItem">15 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>HYDROCHLOROTHIAZIDE</strong> (HYDROCHLOROTHIAZIDE) </td>
<td class="formItem">HYDROCHLOROTHIAZIDE</td>
<td class="formItem">25 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM OXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE (TYPE H)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 6000</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (biconvex) </td>
<td class="formLabel">Size</td>
<td class="formItem">14mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">G;205</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:68462-205-30</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:68462-205-01</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:68462-205-10</td>
<td class="formItem">1000  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA090718</td>
<td class="formItem">03/18/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Glenmark Generics Inc., USA
							(130597813)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Glenmark Generics Limited</td>
<td class="formItem"></td>
<td class="formItem">677318665</td>
<td class="formItem">ANALYSIS(68462-207, 68462-206, 68462-205), MANUFACTURE(68462-207, 68462-206, 68462-205)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Ipca Laboratories Limited</td>
<td class="formItem"></td>
<td class="formItem">862179827</td>
<td class="formItem">API MANUFACTURE(68462-207, 68462-206, 68462-205)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 1/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>30b478aa-eb7f-4a97-9cd0-edfc0f368e7a</div>
<div>Set id: e71002c8-3463-4950-b984-c4eee356a5f2</div>
<div>Version: 9</div>
<div>Effective Time: 20130131</div>
</div>
</div> <div class="DistributorName">Glenmark Generics Inc., USA</div></p>
</body></html>
